ArticleOncogene2011
Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.
Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2013Guideline
- Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Archives of pathology & laboratory medicine · 2013Guideline
- Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations S768I, S768N, D761N.Computational and structural biotechnology journal · 2025Article
- Natural History and Real-World Treatment Outcomes for Patients With NSCLC HavingJTO clinical and research reports · 2024Article
- Racial disparities in the genetic landscape of lung cancer.Cancer health disparities · 2022Article
- EGFR and BRAF mutations in inverted sinonasal papilloma - a more complex landscape?Virchows Archiv : an international journal of pathology · 2021Article
- EGFR exon 20 insertion mutations in non-small cell lung cancer.Translational cancer research · 2020Review
- Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.Clinical lung cancer · 2020Article
- Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.Scientific reports · 2019Article
- HER2Journal of cellular physiology · 2019Article
- Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.Cancer science · 2018Article
- Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.Medical oncology (Northwood, London, England) · 2018Article
- Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.Science translational medicine · 2013Article
- Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?Lung cancer (Amsterdam, Netherlands) · 2013Article
- EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data.Translational lung cancer research · 2013Review
- Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.Cancer science · 2013Article
- Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.Current pharmaceutical design · 2013Article
- Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.Cell death & disease · 2012Article
- Cancer genes in lung cancer: racial disparities: are there any?Genes & cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Epidermal growth factor receptor (EGFR) mutations are predictive markers for response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC). The most common mutations, exon 19 short deletions and exon 20 point mutation (L858R), activate the tyrosine kinase and confer sensitivity to EGFR-TKIs. However, the function and sensitivity of rare mutations to EGFR-TKIs are unknown. In this study, we found five EGFR mutations out of 16 patients with NSCLC of African-American descent. The frequency of such mutations in this patient population appears to be significantly higher than previously reported. Two of them (N771GY and A767-V769dup) are rare insertion mutations located in exon 20. Using YFP-tagged EGFR mutants, we demonstrated that the mutations confer increased kinase activity, but no sensitivity to erlotinib at clinically available concentrations. In addition, we examined efficacy of PF00299804, an irreversible EGFR-TKI. Although the drug failed to show efficacy to T790M and S768N mutations, the exon 20 insertion mutations were sensitive to PF00299804. These data suggest that rare mutations in exon 20 are resistant to erlotinib but may be sensitive to irreversible inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.